<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087096</url>
  </required_header>
  <id_info>
    <org_study_id>20187525</org_study_id>
    <nct_id>NCT04087096</nct_id>
  </id_info>
  <brief_title>Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery</brief_title>
  <official_title>Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Francisco VA Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery leads to bone loss and increases fracture risk. This study evaluates
      whether denosumab can prevent the high-turnover bone loss that occurs after Roux-en-Y Gastric
      Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bariatric surgery is a highly effective weight loss treatment, but one of the unintended side
      effects of these procedures is high-turnover bone loss and metabolic bone disease. Denosumab
      is a monoclonal antibody to RANKL that acts as a potent inhibitor of bone resorption. The
      investigators are conducting a randomized placebo-controlled trial to evaluate the ability of
      denosumab to prevent bone loss after RYGB or SG surgery in older adults. At the conclusion of
      the study, all participants will be given zoledronic acid.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in total hip bone mineral density</measure>
    <time_frame>Pre-operative baseline to post-operative month 19</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Bone Loss</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60mg subcutaneous injection every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection every 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab will be administered at postoperative months 1, 7, and 13</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered at postoperative months 1, 7, and 13</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>Zoledronic Acid 5mg will be administered intravenously at postoperative month 19</description>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Reclast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Postmenopausal women who are planning RYGB or SG surgery

          -  Men aged â‰¥ 50 years who are planning RYGB or SG surgery

        Exclusion criteria:

          -  Prior bariatric surgery

          -  Weight = 400 lbs (due to limitations of bone imaging equipment)

          -  Renal disease

          -  Hypercalcemia or hypocalcemia

          -  Hypomagnesemia

          -  Serum 25-OH vitamin D (25OHD) &lt; 20 ng/mL

          -  Hyperparathyroidism

          -  Liver disease (AST or ALT &gt; 2 x upper normal limit)

          -  HCT &lt; 32%

          -  History of malignancy (except basal cell carcinoma) in the past 1 year

          -  Significant cardiopulmonary disease

          -  Major psychiatric disease

          -  History of celiac disease or inflammatory bowel disease

          -  Excessive alcohol or substance abuse

          -  Paget's disease, primary hyperparathyroidism, or any other known congenital or
             acquired bone disease other than osteoporosis

          -  Current hyperthyroidism or use of levothyroxine with TSH &lt; 0.1 uIU/mL

          -  Current use of loop diuretics

          -  Current use or use in the past 12 months of oral bisphosphonates or DMAB

          -  Current use or use within the past 3 months of SERMs or calcitonin

          -  Current use or use within the past 3 months of estrogen

          -  Use of testosterone therapy if dose has changed within the last 3 months, or if dose
             change or discontinuation is planned in the upcoming 18 months

          -  Any current or previous use of teriparatide, strontium, or any parenteral
             bisphosphonate

          -  Use of oral or parenteral glucocorticoids for more than 14 days within the past 6
             months

          -  Extensive dental work involving extraction or dental implant within the past 2 months
             or planned in the upcoming 18 months

          -  DXA BMD T-score of &lt; -3.0 at PA spine, total hip, or femoral neck

          -  Current use of anti-VEGF drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mike Cheney, NP</last_name>
    <phone>617-643-9720</phone>
    <email>mccheney@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne Schafer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Cheney, NP</last_name>
      <email>mccheney@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lindeman KG, Greenblatt LB, Rourke C, Bouxsein ML, Finkelstein JS, Yu EW. Longitudinal 5-Year Evaluation of Bone Density and Microarchitecture After Roux-en-Y Gastric Bypass Surgery. J Clin Endocrinol Metab. 2018 Nov 1;103(11):4104-4112. doi: 10.1210/jc.2018-01496.</citation>
    <PMID>30219833</PMID>
  </reference>
  <reference>
    <citation>Yu EW, Kim SC, Sturgeon DJ, Lindeman KG, Weissman JS. Fracture Risk After Roux-en-Y Gastric Bypass vs Adjustable Gastric Banding Among Medicare Beneficiaries. JAMA Surg. 2019 Aug 1;154(8):746-753. doi: 10.1001/jamasurg.2019.1157.</citation>
    <PMID>31090893</PMID>
  </reference>
  <reference>
    <citation>Schafer AL, Kazakia GJ, Vittinghoff E, Stewart L, Rogers SJ, Kim TY, Carter JT, Posselt AM, Pasco C, Shoback DM, Black DM. Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture Occur Early and Particularly Impact Postmenopausal Women. J Bone Miner Res. 2018 Jun;33(6):975-986. doi: 10.1002/jbmr.3371. Epub 2018 Feb 5.</citation>
    <PMID>29281126</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elaine W. Yu</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

